U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07768371) titled 'A 52-week Study of Remibrutinib in IgE-mediated Food Allergy' on Aug. 12.
Brief Summary: The purpose of this Phase III study is to evaluate the clinical efficacy and safety of remibrutinib in participants with peanut, or cow's milk ("milk", cooked and uncooked) or hen's egg ("egg", cooked and uncooked) immunoglobulin E (IgE)- mediated allergy in comparison to placebo.
Study Start Date: Sept. 11
Study Type: INTERVENTIONAL
Condition:
IgE-Mediated Food Allergy
Peanut Allergy
Cow Milk Allergy
Egg Allergy
Intervention:
DRUG: Remibrutinib
Oral administration of remibrutinib.
DRUG: Placebo
Oral administration of placebo.
Recruitm...